tbuckley/cabot-search huggingface dataset:
Free thyroxine in serum in relation to thyroid function
Authors: B. G. Anderson
Journal: JAMA (1968)

The concentration of free thyroxine (FT<sub>4</sub>) in serum, measured by a direct method, was 1.77 ± 0.25 mμg/100 ml (mean ± SD) in normal euthyroid adults, 8.47 ± 2.87 in hyperthyroid patients, and 0.54 ± 0.29 in hypothyroid patients. Pregnant euthyroid patients and normal women taking estrogens had increased values for proteinbound iodine (PBI) in serum, while values for the resin uptake of liothyronine I 131 (RT<sub>3</sub>) were decreased; but free thyroxine values were normal or slightly decreased. Euthyroid patients with various chronic diseases had decreased PBI values in association with increased RT<sub>3</sub>values, but free thyroxine values were normal. Acutely or severely ill euthyroid patients had increased free thyroxine values that often exceeded the normal range. The correlation between values for free thyroxine and the PBI•RT<sub>3</sub>product was good in all groups except the sick euthyroid patients. The PBI•RT<sub>3</sub>product closely reflected the state of thyroid function in all of the groups of patients.
Canadian Journal of Biochemistry, Ottawa
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial Association.—
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial Board
Authors: George Bartley, Henry Jampel, Daniel Albert, Andrew Schachat, Anita Agarwal, T Iqbal, Ike Ahmed, Canada Esen, K Akpek, Jayakrishna Ambati, Tin Aung, Singapore Bengtsson, James Brandt, Wiley Chambers, Balwantray Chauhan, Emily Chew, Michael Chiang, Helen Danesh-Meyer, Marjan Farid, Steven Gedde, Mingguang He
Journal: Ophthalmology (2015)
Critical Assessment of Epidemiologic Studies on the Human Carcinogenicity of 1,3-Butadiene
Authors: Philip J. Landrigan
Journal: Environmental Health Perspectives (1990)

1,3-Butadiene, a major ingredient of synthetic rubber, has been shown to be carcinogenic in two animal species. To assess the possible human carcinogenicity of 1,3-butadiene, a critical review was undertaken of the epidemiologic literature. An early retrospective study of 8017 males employed in tire manufacturing found excess mortality for lymphatic and hematopoietic neoplasms in production workers (standardized mortality ratio, SMR = 560); these workers were exposed to 1,3-butadiene as well as to styrene and possibly to benzene. A recently updated epidemiologic study of 2568 workers at a butadiene manufacturing plant in Texas reported low mortality overall (SMR = 84) but found excess deaths for lymphosarcoma and reticulum cell sarcoma (SMR = 229). A retrospective study of workers employed at two synthetic rubber plants in Texas found excess mortality for lymphatic and hematopoietic malignancies in the older of these facilities; the excesses for lymphosarcoma (SMR = 224) and leukemia (SMR = 278) were most significant in wartime workers. A large, recently updated retrospective study of 12,113 workers employed in eight synthetic rubber manufacturing plants in the United States and Canada found excess mortality for lymphatic and hematopoietic cancer in production workers; the SMR for other lymphatic cancers in white production workers was 230, and the SMR for all lymphatic malignancies in black production workers was 507. These updated epidemiologic results strongly suggest an etiologic association between occupational exposure to 1,3-butadiene and human cancer. It is reasonable, therefore, to conclude that there now exists at least limited evidence for the human carcinogenicity of 1,3-butadiene.
A CASE OF GENERAL DERMATITIS DUE TO THE EXTERNAL USE OF ORTHOFORM
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PRESENT STATUS OF TYPHOID FEVER.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).
Authors: Sundar Jagannath, David Siegel, Paul Richardson, Amitabha Mazumder, Jens Sydor, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, Jeffrey Tong, Vito Palombella, Ken Anderson, Julian Adams, David Grayzel
Journal: Blood (2005)
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells
Authors: Igor M. Belyakov, Scott A. Hammond, Jeffrey D. Ahlers, Gregory M. Glenn, Jay A. Berzofsky
Journal: Journal of Clinical Investigation (2004)

Transcutaneous immunization (TCI), the application of vaccines on the skin, induces robust systemic and mucosal antibodies in animal models and in humans. The means by which mucosal immune responses to vaccine antigens are elicited by TCI has not been well characterized. We examined the effect of TCI with an HIV peptide vaccine on the induction of mucosal and systemic CTL responses and protective immunity against mucosal challenge with live virus in mice. Robust HIV-specific CTL responses in the spleen and in the gut mucosa were detected after TCI. The responses were dependent upon the addition of an adjuvant and resulted in protection against mucosal challenge with recombinant vaccinia virus encoding HIV gp160. Although it is clear that adjuvant-activated DCs migrated mainly to draining lymph nodes, coculture with specific T cells and flow cytometry studies with DCs isolated from Peyer’s patches after TCI suggested that activated DCs carrying skin-derived antigen also migrated from the skin to immune-inductive sites in gut mucosa and presented antigen directly to resident lymphocytes. These results and previous clinical trial results support the observation that TCI is a safe and effective strategy for inducing strong mucosal antibody and CTL responses.
The Finances of the American Medical Association.
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contents
Authors: Didier Lebrec, T Sauerbruch, Jesus Prieto, M Strazzabosco, Andrew Burroughs, J Bosch, Yun-Fan Liaw, A Weiler-Normann, M Peyrou, S Cle ´ment, C Maier, L Bourgoin, E Branche, S Conzelmann, V Kaddai, M Foti, F Negro, A Gla, M Eisenhardt, P Kokordelis, B Kra ¨mer, F Wolter, H Nischalke, C Boesecke, J Rockstroh, U Spengler, J Nattermann, C He ´zode, H Fontaine, C Dorival, D Larrey, F Zoulim, V Canva, V De Ledinghen, T Poynard, D Samuel, M Bourlie, J.-P Zarski, J.-J Raabe, L Alric, P Marcellin, G Riachi, P.-H Bernard, V Loustaud-Ratti, S Me, A Tran, L Serfaty, A Abergel, X Causse, V Martino, D Guyader, D Lucidarme, V Grando-Lemaire, P Hillon, C Feray, T Dao, P Cacoub, I Rosa, P Attali, V Petrov-Sanchez, S Zhang, B Saha, K Kodys, G Szabo, D.-Z Xu, X.-Y Wang, X.-L Shen, G.-Z Gong, H Ren, L.-M Guo, A.-M Sun, M Xu, L.-J Li, X.-H Guo, Z Zhen, H.-F Wang, H.-Y Gong, C Xu, N Jiang, C Pan, Z.-J Gong, J.-M Zhang, J Shang, J Xu, Q Xie, T.-F Wu, W.-X Huang, Y.-G Li, Z.-H Yuan, B Wang, K Zhao, Y.-M Wen, M Papp, N Sipeki, Z Vitalis, T Tornai, I Altorjay, I Tornai, M Udvardy, K Fechner, S Jacobsen, B Teegen, A Sumegi, G Veres, P Lakatos, J Kappelmayer, P Antal-Szalmas, V Ahluwalia, J Wade, L Thacker, K Kraft, R Sterling, R Stravitz, M Fuchs, I Bouneva, P Puri, V Luketic, A Sanyal, H Gilles, D Heuman, J Bajaj, C Fagundes, R Barreto, M Guevara, E Garcia, E Sola, E Rodrı ´guez, I Graupera, X Ariza, G Pereira, I Alfaro, J Ferna ´ndez, E Poch, P Gine, S Piano, S Rosi, G Maresio, S Fasolato, M Cavallin, A Romano, F Morando, E Gola, A Frigo, A Gatta, P Angeli, M Carbone, S Bufton, A Monaco, L Griffiths, D Jones, J Neuberger, D Uzi, L Barda, V Scaiewicz, M Mills, T Mueller, A Gonzalez-Rodriguez, A Valverde, T Iwawaki, Y Nahmias, R Xavier, R Chung, O Shibolet, G.-Z Jin, W.-L Yu, H Dong, W.-P Zhou, Y.-J Gu, H Yu, X Lu, Z.-H Xian, Y.-K Liu, W.-M Cong, M.-C Wu, Y Chang, C Liu, J Yang, G Liu, F Feng, J Tang, L Hu, F Jiang, C Chen, R Wang, Y Yang, X Jiang, L Chen, B Ho ¨chst, F Schildberg, P Sauerborn, Y Ga ¨bel, H Gevensleben, D Goltz, L Heukamp, A Tu, M Ballmaier, F Gieseke, I Mu ¨ller, J Kalff, C Kurts, P Knolle, L Diehl, -S Wong, S.-M Chan, -H Wong, -K Cheung, -W Chu, -W Yeung, -L Chim, -Y Lai, M.-M Sea, -L Chan, J.-Y Sung, J Woo, -Y Chan
Journal: Journal of Hepatology (2013)
Monoclonal antibodies raised against Guillain-Barré syndrome–associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations
Authors: Carl S. Goodyear, Graham M. O’Hanlon, Jaap J. Plomp, Eric R. Wagner, Ian Morrison, Jean Veitch, Lynne Cochrane, Roland W. M. Bullens, Peter C. Molenaar, Joe Conner, Hugh J. Willison
Journal: Journal of Clinical Investigation (1999)

Table 1Ganglioside and LPS binding characteristics of mAb's cloned from mice immunized with C. jejuni LPS
The Eye in Systemic Disease
Authors: Frank R. Burns
Journal: JAMA (1990)

The need for a comprehensive text that covers the broad topic of the effect of systemic diseases upon the eye is quite evident for both ophthalmologists and practitioners in general medical fields. The editors have coordinated the efforts of 320 contributors from an extremely broad range of areas. An extensive number of contributors from the ophthalmic academic community is complemented by an impressive representation from specialists in dermatology, genetics, neurology, immunology, oncology, hematology, toxicology, and infectious disease. Surgical contributions from the fields of neurosurgery, plastic surgery, and obstetrics/gynecology have also been included. Additionally, specialists from the fields of public health, pathology, nutrition, and cell biology have contributed to the 230 chapters. The editors mention in the preface their intention of offering an overview of the individual diseases represented, thus creating a concise reference text for both the primary care provider and the specialist. The book is organized according to clinical
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Mary-Ellen Taplin, Arif Hussain, Satish Shah, Neal D. Shore, Manish Agrawal, William Clark, William Jeffery Edenfield, Luke T. Nordquist, Oliver A Sartor, James E. Butrynski, Gurkamal S. Chatta, Mark T. Fleming, William K. Oh, Bill Bradley, Jessica Piel, David Nash, Gozde Colak, Jian Li, Claudia Lebedinsky, Emmanuel S. Antonarakis
Journal: Journal of Clinical Oncology (2019)

TPS335 Background: EZH2 is frequently mutated and/or overexpressed in numerous cancers. High EZH2 expression is correlated with poor outcomes in prostate cancer patients (Varambally, 2002). EZH2 inhibition combines synergistically with anti-androgen therapies in preclinical models of advanced prostate cancer, suggesting epigenetic reprogramming as a pathophysiologic mechanism to enhance the combination therapy (Ku, 2017; Xiao 2018; Constellation, unpublished). CPI-1205 is a potent, selective, and cofactor-competitive inhibitor of wild type and mutant EZH2 catalytic activity, which demonstrates anti-proliferative effects in prostate and other cancer cell models. Methods: We present a Phase 1b/2 multicenter study of CPI-1205 combined with either E or A/P in patients with mCRPC, which includes phase 1 dose escalation, an expansion cohort in heavily pretreated patients (HPEC), and a randomized phase 2 study. Key eligibility criteria include progressive mCRPC in patients previously treated with a second-generation androgen inhibitor, ECOG 0-1, and measurable or non-measurable disease. During the phase 1b, patients will receive CPI-1205 continuously in 28-day cycles combined with the standard dose of either E (160mg PO once daily) or A/P (1000mg PO once daily/5 mg BID). The primary objective in Phase 1b is to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of CPI-1205 combined with either E or A/P. Secondary objectives include safety, pharmacokinetic and pharmacodynamic profiles, and anti-tumor activity. The HPEC arm, with Simon’s 2-stage design, may begin with the regimen that is deemed safe by the study safety committee. The primary endpoint of the HPEC arm is objective response rate (ORR) per PCWG3, with a requirement ≥ 1 measurable lymph node at baseline. Once RP2D is established, we will start a randomized Phase 2 trial of E or A/P combined with CPI-1205 vs. E or A/P alone. The co-primary endpoint includes PSA50 and composite response rate (either CTC 30% reduction or ORR per PCWG3). Patient accrual in US sites began in December 2017. Clinical trial information: NCT03480646.
Effects of alcohol on hypoxia
Authors: J. L. Nettles
Journal: JAMA (1965)

In an effort to determine the effects of alcohol upon the time of useful consciousness of a subject when he is suddenly subjected to hypoxic conditions, ten normal subjects were taken to an atmosphere simulating 25,000 feet (288 mm Hg) in an altitude chamber. After their oxygen masks were removed, they performed various tasks requiring mental and physical coordination until definite hypoxic symptoms were manifested. Later, these same subjects were submitted to identical conditions after the administration of 0.5 cc of 100-proof whiskey per pound of body weight. Blood alcohol levels were determined upon the completion of experiment. A comparison of results demonstrated a 38% reduction in the time of useful consciousness under such hypoxic conditions. In the age of pressurized aircraft subject to rapid decompression, this 38% reduction may easily spell the difference between life and death.
Synaptic vesicle exocytosis
Authors: T. Reese
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgical Diagnosis. Volume I and Volume II. [Volume III and Index to be ready in March, 1930.]
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Journal of the Medical Sciences, Philadelphia
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Haematuria clinics
Authors: A B Paul, G D Chisholm, D A Collie, S R Wild
Journal: BMJ (1994)

and especially in KwaZulu, the Zulu homeland, we have an extreme shortage of medical staff.The KwaZulu Department of Health has divided itself into six regions, each of which contains about five wards centred on their own hospital.Specialists are based at the regional hospitals but are encouraged to visit the ward hospitals for teaching and to provide services.The ward hospitals are rural.Around each ward hospital is a network of residen- tial clinics staffed by nurses trained in primary health care.Patients with conditions beyond the nurses' competence are referred to the ward hos- pital for care.Rural hospitals are therefore very much part of the community, and a good rural physician can have considerable contact with the local people.Because the rural hospitals are up to 200 km